Dual immunotherapy plus chemo may shrink cervical tumors before surgery
NCT ID NCT07646301
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy before surgery in 103 women with locally advanced cervical cancer. The goal is to see if this approach can shrink tumors enough to allow less extensive surgery, potentially preserving more of the cervix. Participants will receive up to 4 cycles of the drug combo, then surgery, and possibly maintenance therapy if they respond well.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Iparomlimab and tuvonralimab (a dual immunotherapy drug) plus paclitaxel and platinum chemotherapy
- What this could lead to
- If successful, this approach could shrink tumors enough to allow less invasive surgery, preserving more of the cervix and potentially improving quality of life.
- What could go wrong
- This is an early phase 2 trial with only 103 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation of organs, and not all patients will respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could vitamin d predict cervical cancer treatment success?
- One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
- Can a triple-threat approach wipe out cervical cancer before surgery?
- Particle beam and immune therapy join forces against cervical cancer
- Protein clues may predict cervical cancer return
- Can a simple WhatsApp message save lives? chile tests new screening nudge